Neoplasms, Hematologic Active Not Recruiting Phase 1 / 2 Trials for Ibrutinib (DB09053)

Also known as: Hematologic Neoplasm / Hematologic Neoplasms

IndicationStatusPhase
DBCOND0056760 (Neoplasms, Hematologic)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02329847A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic MalignanciesTreatment